Healthtech Startups

Abartys Health provides a centralized healthcare data hub for managing medical records across providers, patients, and administrators. Operating in Latin America and the United States, the platform serves doctors, hospitals, labs, and other healthcare providers seeking secure, interoperable data management solutions.

1 investor

ABB Optical Group is the leading distributor of contact lenses, specialty vision products, and related services to eye care professionals across the United States. The company supplies products to nearly two-thirds of U.S. eye care providers and operates its own manufacturing and technology platforms to enhance practice operations and profitability.

1 investor

GOGOTECH develops ABBY, a hybrid manual/power-assist/electric "smart" wheelchair with a smart controller, machine vision (cameras and sensors), and IoT cloud connectivity, priced below $4,000. The company plans to sell directly to consumers as a personal electric vehicle and, pending FDA 510(k) clearance, as a Class II medical device through B2B distributors, targeting both developed and developing markets.

1 investor

Abby Health provides telehealth and primary care services for Australians, focusing on continuity of care by maintaining patient histories and enabling consistent doctor-patient relationships. The platform aims to address rural healthcare access gaps and system fragmentation through a patient-first digital health model.

1 investor

ABclonal develops and manufactures reagents for life science research, including recombinant rabbit monoclonal and polyclonal antibodies, recombinant proteins, molecular biology enzymes and kits, immunoassay ELISA kits, and NGS library preparation products. Its catalog using the proprietary SMab technology serves research institutions and labs in areas such as cell biology, immunology, and diagnostics.

1 investor

VitalEngine provides a platform that links hospitals with their referring providers and integrates with EMR, PACS/DICOM imaging, and scheduling systems to share images, messages, and cases in real time. It targets hospitals and health networks seeking to reduce referral leakage and convert referrals into scheduled procedures.

1 investor

AbelZeta develops T cell immunotherapies, advancing pipeline drug candidates through early-stage and investigator-initiated clinical trials to treat cancer and immune and inflammatory (I&I) diseases. The company runs an in-house platform for cell therapy development and partners with global pharmaceutical firms for clinical development and commercialization.

1 investor

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.

1 investor

Abilia develops assistive technology that provides cognitive support, seizure detection, attention care alarms, and virtual care delivery to help people with disabilities or care needs live more independently. The company applies over 50 years of experience serving individuals requiring everyday support and their caregivers.

1 investor

Ability is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer. Its AbiLeap discovery engine uses AI and a database of antibody sequences to generate fully-human monospecific and bispecific antibodies, with a lead program targeting inflammatory skin diseases and other candidates for solid tumors.

1 investor

Abingworth is a venture capital and private equity firm specializing in life sciences and healthcare investments across seed, development, and clinical co-development stages. The firm manages 15 dedicated funds and has invested in over 200 companies across the United States and Europe.

1 investor

AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.

1 investor

ABio-X is a life sciences incubation platform that creates and invests in biotech and pharmaceutical companies developing innovative medicines and technologies. The platform provides capital, operational support, and access to experienced entrepreneurs and industry networks to accelerate drug development pipelines.

1 investor

Abionic develops the abioSCOPE, a near-patient rapid diagnostic platform that uses nanofluidic immunoassay technology to deliver lab-quality results from a single drop of blood within minutes. The platform is designed for clinical settings including hospitals and laboratories to enable early detection of conditions such as sepsis.

1 investor

ABL Health is a community-based healthcare organisation focused on eradicating health inequalities by supporting people to become active participants in their own health. The organisation works with local communities and the wider healthcare system in the UK to deliver evidence-based health and wellbeing services.

1 investor

Boston Scientific develops cardiac electrophysiology mapping and ablation systems used by physicians to treat atrial fibrillation and other arrhythmias, including high-density mapping, pulsed field ablation, and electrographic flow source identification. Its systems support procedures such as pulmonary vein isolation through real-time catheter visualization and advanced electrogram analysis.

1 investor

1 investor

Able Sciences works on cell engineering to develop next-generation disease-fighting cells.

1 investor

Abliva develops treatments for primary mitochondrial disease, a rare orphan disease caused by impaired cellular energy metabolism in the mitochondria. The company focuses on pharmaceutical research and development to address an unmet medical need where no effective treatments currently exist.

1 investor

Abologix is a biopharmaceutical company developing two monoclonal antibodies that target JAM-C and Olfactomedin-like protein 3 (Olfml3) for oncology indications. It is a spin-out from the University of Geneva and Geneva University Hospitals.

1 investor

A healthcare software company that provides patient transfer, admission, discharge planning, and post-acute care placement solutions for hospitals and health systems. The platform uses workflow automation and predictive analytics to optimize patient flow, bed capacity, and care coordination across facilities.

1 investor

About Health produces Probiotic Plus, a digestive health supplement combining two probiotic strains with herbal extracts for adults seeking to support gut health, immune function, and energy levels. The product is manufactured in New Zealand and available for direct purchase.

1 investor

ABSCINT develops non-invasive in vivo PET imaging diagnostics using single-domain antibodies (sdAbs) as radiolabeled targeting agents, including an anti-HER2 PET tracer for whole-body imaging. Its technology is aimed at physicians diagnosing and monitoring HER2-driven cancers such as breast cancer, supporting patient identification, disease assessment, and treatment monitoring.

1 investor

Absolute Dental is a dental practice providing preventive oral care, routine teeth cleanings, and oral health exams across multiple Nevada locations. The practice serves families and individuals of all ages, from pediatric to senior patients.

1 investor